The FDA granted Rigel Pharmaceuticals (RIGL) orphan status for its treatment of myelodysplastic syndromes.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Rigel Pharmaceuticals price target raised to $25 from $15 at Cantor Fitzgerald
- Rigel Pharmaceuticals price target lowered to $20 from $27 at B. Riley
- Rigel Pharmaceuticals announces initial data from Phase 1b study of R289
- Rigel Pharmaceuticals price target raised to $27 from $17 at B. Riley
- Rigel Pharmaceuticals announces R289 granted Fast Track designation by FDA